[Problems of pharmacological research and clinical study of new drugs].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M D Mashkovskiĭ.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The biochemical mechanism of action produced by a new antidepressant pyrazidol (1,10-trimethylene-8-methyl-1, 2, 3, 4-tetrahydropyrazino[1,2-a] indole hydrochloride) includes the inhibitory influence on the neuronal uptake of norepinephrine and a reversible comparatively short-lived inhibitory effect on the MAO activity.
When used in doses of 20-50 mg/kg on models of acute exudative and chronic propliferative inflammation in rats pyridinolcarbamate inhibited the development of an exudative reaction provoked by bradykinine and silver nitrate and did not influence the effects of histamine and dextran, nor the chronic proliferative inflammatory process. As concerns its antiexudative action pyridinolcarbamate is superior to butadion. The effect of the drug comes from its selective antibradykinine action.
The influence of pyridinolcarbamate (parmidine) on raising the tonicity of bronchial and intestinal muscles in guinea pigs, and also on the edema of the paw in rats, induced with bradykinin was studied. Parmidin displays a specific antibradykinin activity and mitigates the effects of bradykinin in all the objects under investigation, without exercising any influence on the spasmogenic action of histamine, serotonin and acetylcholine.
The experiments on albino rats demonstrated that antidepressants pyrazidol, imipramine, incazane, moclobemide and to a lesser degree azaphen reduce the amnesic effects of electroshock and scopolamine in the rats with the acquired conditioned reaction of passive avoidance. The studied antidepressants decrease also the disturbing action of alcohol on the learning of rats of the conditioned reaction of active avoidance.
In experiments on conscious normotensive male Wistar rats the new antidepressants, reversible MAO-A inhibitors, pyrazidole and incazane, as well as moclobemid increased the pressor effect of orally administered tyramine. The drugs potentiated also the pressor effect of intravenous tyramine. More prolonged potentiation of tyramine action was produced by moclobemid, less prolonged by incazane. The potentiation by the studied MAO-A inhibitors of the pressor effect of tyramine reflects the inhibition of the activity of MAO-A and the first-pass metabolism of tyramine in the gut and liver, as well as the inhibition of intraneuronal MAO activity in noradrenergic nerve endings and the potentiation of sympathetic activity.
Explore the source record for details and available documents.
Effect of some MAO inhibitors on rotational behavior induced by d-amphetamine in unilaterally 6-OHDA-lesioned rats was studied. Among all MAO inhibitors tested only 1-deprenyl induced rotational behavior. Nialamide, chlorgiline, pyrazidol and inkazan dose-dependently enhanced rotational behavior induced by 2 mg/kg i. p. d-amphetamine and pargiline depressed it. Nialamide and inkazan greatly enhanced rotational behavior induced by 0.5 mg/kg i. p. d-amphetamine. It is suggested that nialamide and inkazan may have similar effects on DA-ergic neurotransmission.
Some derivatives of 2-(3-amino-2-hydroxypropoxy)phenoxymethyl isoxazole possess beta- and alpha-adrenoblocking activity. 3-Methyl-4-chlor-5-(3-isopropylamino-2-hydroxypropoxy)phenoxymethyl isoxazole hydrochloride (compound OF-4452) is the most active of the compounds studied. As to the beta-adrenoblocking activity, this compound given in vivo and in vitro compares very favourably with propranolol, oxprenolol and labetalol, in particular; as regards the alpha-adrenoblocking action, it is not inferior to the latter drug. Compound OF-4452 has a partial agonist activity and nonspecific membrane-stabilizing action. It displays antifibrillatory and antiarrhythmic activity as well.
Inkazan and pyrazidol given to mice in certain doses were found to reduce the sedative action of diazepam without decreasing its anxiolytic effect but at the same time enhancing the anticonvulsive one. Imipramine diminishes the hypolocomotor action of diazepam and also its anxiolytic effect and exerts no influence on the anticonvulsive effect. All studied antidepressants diminish the hypnotic action on nitrazepam in mice but only inkazan and pyrazidol decrease the sedative-hypnotic effect of nitrazepam in rats. In connection with the lack of the influence on the anxiolytic effect, inkazan and pyrazidol may be used to decrease the sedative side effects of benzodiazepines.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The antihistaminic and antiserotonin properties of 16 new tropine esters, analogues of atropine, tropacin and tropaphen, were studied. All of them were found to lessen the spasmogenic effects of histamine and serotonin. The intensity of the antihistaminic and antiserotonin action of the drugs varied depending upon the structure of the radical at the alpha-carbon atom in the acidic part of the molecule. Both types of the activity are most marked in the desoxymethyl propyl and butyl analogues of atropine. The absence of the oxymethyl group at alpha-carbon in the series of atropine analogues is shown to facilitate the manifestation of the antihistaminic activity.
In experiments on unanesthetized rabbits it was found that the effects of ketamine and kalipsol were characterized by a decrease of the negative phase amplitude of the primary response (PR) of evoked potentials (EP) and the secondary positive deviation of EP of the cortical somatosensory region.